| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥61.1B | ¥58.4B | +4.6% |
| Operating Income | ¥17.9B | ¥15.2B | +17.3% |
| Ordinary Income | ¥18.4B | ¥15.4B | +19.2% |
| Net Income | ¥12.1B | ¥11.2B | +8.2% |
| ROE | 22.1% | 19.9% | - |
FY2025 results show revenue of 61.1B yen (YoY +4.6%), operating income of 17.9B yen (+17.3%), ordinary income of 18.4B yen (+19.2%), and net income of 12.1B yen (+8.2%). The company achieved revenue growth with significantly stronger profit expansion, demonstrating operational leverage. Operating margin improved to 29.3% from 26.1% in the prior year, marking a 3.2 percentage point improvement. Gross profit margin remained strong at 65.2%, while SG&A expenses grew at a slower pace than revenue. The company executed substantial share buybacks of 10.0B yen alongside operating cash flow generation of 16.5B yen, resulting in strong free cash flow of 13.6B yen.
Revenue increased 4.6% YoY to 61.1B yen, driven primarily by the core Medical Business segment which grew 3.6% to 56.9B yen. The Public Business segment expanded significantly by 22.7% to 3.6B yen, while the HealthTech Business segment increased 11.4% to 0.6B yen. The Medical Business, representing 93.1% of consolidated revenue, remains the primary growth driver with its healthcare systems development, sales, and medical data analytics operations. The Public Business segment's strong growth reflects expansion in DX solutions centered on document management systems for public sector clients. Operating income surged 17.3% to 17.9B yen, substantially outpacing revenue growth due to enhanced operating leverage. The operating margin improved 3.2 percentage points to 29.3%, as the high gross margin of 65.2% was maintained while SG&A expense ratio declined to 35.9% from 37.5%. The Medical Business segment's operating income increased 14.6% to 18.9B yen with margin improvement, while the Public Business segment grew 8.6% to 1.1B yen in operating income. The HealthTech Business segment's operating loss narrowed from negative 0.23B yen to negative 0.21B yen, showing gradual improvement in its development phase. Ordinary income of 18.4B yen exceeded operating income by 0.5B yen, reflecting net non-operating gains primarily from investment securities and financial income. Net income growth of 8.2% to 12.1B yen lagged behind operating income growth due to a normalized tax burden, with profit before tax at 17.8B yen resulting in an effective tax rate of approximately 28.3%. This represents a "revenue up, profit up with enhanced margin expansion" pattern, characterized by strong operational leverage and core business profitability improvements.
The Medical Business segment generated revenue of 56.9B yen (YoY +3.6%) and operating income of 18.9B yen (+14.6%), representing 93.1% of total revenue and serving as the core business. Operating margin for this segment improved substantially, demonstrating the scalability of healthcare systems and medical data analytics operations. The Public Business segment recorded revenue of 3.6B yen (+22.7%) and operating income of 1.1B yen (+8.6%), contributing 5.8% of total revenue. This segment's strong revenue growth of 22.7% reflects expanding demand for DX solutions in public sector document management and administrative systems. The HealthTech Business segment posted revenue of 0.6B yen (+11.4%) with an operating loss of 0.21B yen, an improvement from the prior year's loss of 0.23B yen. This segment remains in investment phase focused on medical device development and healthcare data processing. Notable margin differences exist, with the Medical Business demonstrating high profitability while HealthTech continues as a strategic investment with negative margins. Segment assets totaled 26.4B yen, with Medical Business representing the largest share at 23.7B yen, reflecting the capital intensity and working capital requirements of the core healthcare IT operations.
[Profitability] ROE of 22.1% represents strong return on equity, with operating margin at 29.3% marking a 3.2 percentage point improvement from 26.1% in the prior year. Net profit margin reached 19.7%, while gross profit margin maintained a high level of 65.2%. [Cash Quality] Cash and deposits of 16.8B yen provide coverage of 1.63x against current liabilities of 10.3B yen. Operating cash flow of 16.5B yen represents 1.36x net income, confirming earnings quality. Free cash flow reached 13.6B yen after capex of 0.4B yen. [Investment Efficiency] Asset turnover ratio stands at 0.90x (revenue 61.1B yen divided by total assets 68.1B yen). Return on assets calculates to 17.8%. Depreciation and amortization of 0.4B yen versus capex of 0.4B yen indicates maintenance-level investment. [Financial Health] Equity ratio of 80.3% reflects strong capitalization with total equity of 54.7B yen against total assets of 68.1B yen. Current ratio of 363.8% (current assets 37.4B yen versus current liabilities 10.3B yen) demonstrates substantial liquidity. Debt-to-equity ratio remains minimal at 0.25x with total liabilities of 13.4B yen. The company maintains net cash position with cash holdings exceeding any borrowings.
Operating cash flow of 16.5B yen represents 1.36x net income of 12.1B yen, confirming cash-backed earnings quality. The operating CF declined 13.0% YoY from 19.0B yen, primarily reflecting working capital movements and timing effects despite improved profitability. Investing cash flow of negative 3.0B yen consisted primarily of capex of 0.4B yen and net changes in investment securities holdings. The company maintains an asset-light model with limited capital intensity, as evidenced by capex representing only 0.7% of revenue. Financing cash flow of negative 14.1B yen was driven by substantial share buybacks of 10.0B yen plus dividend payments, reflecting aggressive shareholder returns. Free cash flow of 13.6B yen (operating CF 16.5B yen minus capex 0.4B yen, plus other investing activities) remains robust and covers total shareholder returns. Cash and deposits increased from 17.3B yen to 16.8B yen, declining modestly by 0.5B yen despite the significant cash outflows for buybacks, demonstrating the underlying cash generation capacity of the business model.
Ordinary income of 18.4B yen compared to operating income of 17.9B yen shows non-operating net contribution of approximately 0.5B yen, primarily comprising equity method gains, dividend income, and interest income from the substantial investment securities portfolio valued at 22.2B yen. Non-operating income represents less than 1% of revenue, indicating core earnings are predominantly driven by operating activities rather than financial gains. The gap between ordinary income and net income of 6.3B yen reflects income taxes of approximately 5.7B yen with an effective tax rate of 28.3%, which is within normal corporate tax parameters. Operating cash flow of 16.5B yen exceeding net income of 12.1B yen by 36% indicates healthy earnings quality with strong cash conversion. Accruals analysis shows operating profit growth of 17.3% supported by corresponding cash flow generation, with no significant red flags regarding earnings manipulation. The company's business model of healthcare IT systems and services generates recurring revenue with predictable cash flows, contributing to sustainable earnings quality.
Full-year guidance calls for revenue of 62.1B yen (YoY +1.6%), operating income of 18.3B yen (+2.2%), and ordinary income of 18.9B yen (+2.6%). Actual results of 61.1B yen revenue and 17.9B yen operating income represent 98.4% and 97.8% achievement rates respectively against full-year targets, indicating guidance is likely achievable or already effectively met depending on reporting timing. The forecast implies Q4 or remaining period contribution of approximately 1.0B yen revenue and 0.4B yen operating income, representing modest incremental growth. Operating margin guidance of 29.5% (18.3B yen divided by 62.1B yen) aligns closely with actual performance of 29.3%, suggesting margin stability. The conservative revenue growth forecast of 1.6% for the full year compared to actual 4.6% YoY growth may reflect management conservatism or anticipated deceleration. EPS forecast of 53.34 yen implies net income projection of approximately 13.4B yen based on average shares outstanding of 25.1 million shares, representing modest growth from actual 50.07 yen EPS. No material revisions or extraordinary assumptions were disclosed in the forecast notes.
Annual dividend forecast of 13.00 yen for the coming year compares to the current period structure. Payout ratio of 33.1% based on reported metrics indicates sustainable dividend policy with room for growth. The company executed significant share buybacks totaling 10.0B yen during the fiscal year, representing substantial capital return alongside dividends. Combined dividends and buybacks result in a high total return ratio, demonstrating management's commitment to shareholder value. Treasury shares increased from 2.2 million shares to a larger position due to the buyback program. The aggressive buyback of 10.0B yen against free cash flow of 13.6B yen indicates that 73.5% of FCF was deployed for share repurchases alone, leaving limited excess for dividends and other purposes. Total shareholder return ratio combining both dividends and buybacks significantly exceeds the dividend-only payout ratio of 33.1%, positioning the company as shareholder-friendly. The sustainability of this dual return approach depends on continued strong free cash flow generation, with the current year's buyback representing an outsized commitment that may not recur at the same scale annually.
First, revenue concentration risk exists with over 90% of sales derived from the domestic Japanese market and 93.1% from the Medical Business segment alone. Any deterioration in domestic healthcare IT investment or regulatory changes affecting healthcare digitalization could materially impact results. Second, the substantial investment securities portfolio of 22.2B yen representing 32.6% of total assets exposes the company to market valuation risk and potential impairment losses, particularly given the volatile nature of equity holdings. This concentration in financial assets creates earnings volatility through non-operating gains and losses. Third, the HealthTech Business segment continues to generate operating losses of 0.21B yen, and while improving, sustained losses in this development-stage business could pressure consolidated profitability if the segment fails to achieve commercialization milestones. The company's capacity to absorb these losses depends on continued strength in the core Medical Business.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates superior profitability metrics compared to typical healthcare IT and enterprise software providers. Operating margin of 29.3% positions substantially above industry medians for software and IT services companies, which typically range from 15% to 25% depending on business model and scale. The company's historical operating margin progression shows consistent expansion from mid-20% levels to current near-30% levels, indicating sustainable competitive advantages in its healthcare systems niche. ROE of 22.1% exceeds typical industry medians of 12-15% for enterprise software companies, reflecting both operational excellence and capital-light business model. Net profit margin of 19.7% ranks in the upper quartile of healthcare IT providers, most of which achieve 10-15% margins. The equity ratio of 80.3% reflects exceptionally conservative capital structure compared to industry medians of 40-60%, providing substantial financial flexibility but potentially under-utilizing financial leverage. Revenue growth of 4.6% aligns with mature healthcare IT providers, though below high-growth SaaS companies achieving 15-25% growth, indicating the company operates in a stable but moderately growing market segment. The company's historical metrics show consistent profitability with operating margin sustaining above 25% over multiple periods, distinguishing it as a high-quality, cash-generative business within healthcare technology.
The company exhibits exceptional profitability characteristics with operating margin expansion to 29.3% and ROE of 22.1%, significantly above industry medians, reflecting strong competitive positioning in healthcare IT systems. Operating leverage is clearly demonstrated through 17.3% operating income growth on only 4.6% revenue growth, indicating scalability and margin expansion potential as the business grows. Cash generation remains robust with operating cash flow of 16.5B yen and free cash flow of 13.6B yen, supporting aggressive shareholder returns of 10.0B yen in buybacks while maintaining a net cash balance sheet with 80.3% equity ratio. The combination of high profitability, strong cash conversion, and conservative capital structure positions the company to sustain and potentially increase shareholder returns. However, revenue growth deceleration to projected 1.6% and heavy dependence on domestic Medical Business (93% of revenue) suggest limited near-term growth catalysts and concentrated market exposure. The substantial investment securities portfolio of 22.2B yen creates non-operating income volatility and represents capital potentially redeployable to core business expansion or enhanced returns if management shifts allocation strategy.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.